Application of znf770 gene in preparation of products for diagnosis and treatment of preeclampsia

A preeclampsia, gene technology, applied in the field of biomedicine, can solve problems such as abnormal expression of multiple genes

Active Publication Date: 2020-08-04
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although many preeclampsia-related genes have been found, such as angiotensinogen (AGT) gene (Ward K, Hata A, Jeunemaitre X, et al. A molecular variant of angiotensiongen associated with preeclampsia. Nature Genet, 1993, 4:59 -61.), prothrombin gene [Kupferminc MJ, Eldor A, Steinman N, et al.Increased frequency of genetic thrombophilia in women with complications of pregnancy.N Engl J Ned,1999,340:9-13], tumor necrosis factor a(TNF a) gene [Rinehart BK, Terrone DA, Lagoo-Deenadayalan S, et al. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interlukin 10 is increased in preeclampsia. Am J Obstet Gynecol, 1999, 181 (4 ):915-920.], etc., but because its occurrence and development involve abnormal expression of multiple genes, further research is still needed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of znf770 gene in preparation of products for diagnosis and treatment of preeclampsia
  • Application of znf770 gene in preparation of products for diagnosis and treatment of preeclampsia
  • Application of znf770 gene in preparation of products for diagnosis and treatment of preeclampsia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Example 1 Screening for Abnormally Expressed Genes in the Placental Tissue of Patients with Preeclampsia

[0063] 1. Organization collection

[0064] The placental tissues of 5 patients with preeclampsia who were delivered in the obstetrics and gynecology department of the hospital were collected, and 5 cases of placental tissues of late-pregnancy pregnant women with normal blood pressure who underwent surgical termination of pregnancy due to social factors or pelvic abnormalities were selected as the normal control group. Multiple pregnancy, infectious diseases, chemical drug dependence, maternal smoking, fetal congenital malformations and other pregnancy complications and complications were all excluded, and the gestational age was strictly verified according to the B-ultrasound data in the first trimester, and the number of days of pregnancy was calculated. Sign the informed consent form before collecting the specimens. The diagnosis and grading standards of preecla...

Embodiment 2

[0101] Example 2 Large sample verification of expression of differentially expressed genes at the transcriptional level

[0102] 1. Organization collection

[0103] According to the standard of Example 1, 35 cases of placental tissues of preeclampsia patients and 40 cases of placental tissues of normal pregnant women were collected.

[0104] 2. Tissue RNA extraction and identification

[0105] Step is with embodiment 1.

[0106] 3. Design and preparation of primers

[0107] The primer sequences for qRT-PCR detection of ZNF770 gene expression and the primer sequences for qRT-PCR amplification of the internal reference GAPDH were designed and synthesized by Sangon Bioengineering (Shanghai) Co., Ltd., and their sequence information was entered into NCBI after searching the UCSC database The primers are designed by the software and confirmed by blast in the gene bank.

[0108] ZNF770 gene primers:

[0109]Upstream primer: 5'-TCAATGTATGGAGTGTAT-3' (SEQ ID NO.1);

[0110] Down...

Embodiment 3

[0133] Embodiment 3 interferes with ZNF770 gene expression

[0134] 1. Design and synthesis of interference RNA

[0135] According to the ZNF770 gene sequence, siRNA was designed and synthesized by Shanghai Gemma Pharmaceutical Technology Co., Ltd. Shanghai Gemma Pharmaceutical Technology Co., Ltd. also provides a negative control siRNA (siRNA-NC) that has no sequence homology with the ZNF770 gene.

[0136] siRNA-ZNF770:

[0137] The sense strand is 5'-AAUAUUGCAAACAUAUGGCCU-3' (SEQ ID NO.5);

[0138] The antisense strand is 5'-GCCAUAUGUUUGCAAUAUUUG-3' (SEQ ID NO.6),

[0139] 2. Culture of placental trophoblast cells

[0140] JEG-3 cells were placed in DMEM high pond medium containing double antibody and 10% fetal bovine serum at 37°C, 5% CO 2 Cultured in an incubator, the culture medium was changed every 24 hours, and the cells were passaged once every 48 hours. Cells in the logarithmic growth phase were used for subsequent experiments.

[0141] 3. Cell transfection

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
cover factoraaaaaaaaaa
Login to view more

Abstract

The invention discloses application of ZNF770 gene as a diagnostic treatment target for preeclampsia. Accordingly, ZNF770 can be used to develop products to diagnose preeclampsia and drugs to treat preeclampsia. Study results of herein provide theoretical basis for clinicians to formulate personalized treatment plans and provide novel pharmaceutical targets to develop preeclampsia drugs.

Description

technical field [0001] The invention relates to the field of biomedicine, and more specifically, the invention relates to the application of the ZNF770 gene in the preparation of products for the diagnosis and treatment of preeclampsia. Background technique [0002] Preeclampsia is one of the main diseases that cause increased maternal and child morbidity and mortality in the field of obstetrics. It has obvious genetic predisposition, and its pathophysiological changes involve multi-system and multi-organ lesions. The etiology and pathogenesis have not yet been fully elucidated. , has always been the focus of obstetrics research. The change of gene expression is the core mechanism to regulate the process of cell life activities. Abnormal metabolic processes or pathological changes, whether controlled by a single gene or a multi-gene system, are essentially caused by differential expression of genes, so they can regulate blood pressure, The genes of body fluid volume, placen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6883A61K45/00A61P15/00
CPCA61K45/00A61P15/00C12Q1/6883C12Q2600/158
Inventor 孙耀兰张冬梅
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap